Literature DB >> 6154092

Interferon activation of "pre-spontaneous killer" (pre-SK) cells and alteration in kinetics of lysis of both "pre-SK" and active SK cells.

S Targan, F Dorey.   

Abstract

Interferon augments spontaneous killer cellular cytotoxicity (SKCC). This modulation may be vital in both tumor resistance and host viral defenses. To date, whether increased numbers of effector cells or activation of individual effector cells is responsible for this augmentation has not been established. Using a single cell assay where SK killing is directly visualized by the reading of trypan blue uptake at various time points by effector-target cell conjugates plated in agarose gel, we measured in vitro alterations in percentage of conjugate formation, number of active SK cells, and kinetics of SK cell lysis at the single cell level after 1 hr of interferon incubation. After interferon, there is no difference in number of cells that bind K-562 targets. This augmentation of cytotoxicity is due to both recruitment of new effector cells and an activation of the lytic process of both the new and already active SK cells.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6154092

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  38 in total

1.  Ability of recombinant interferon gamma in vitro to restore the defective polymorphonuclear-cell- but not lymphocyte-mediated cytotoxic activities in patients with myelodysplastic syndromes.

Authors:  G De Sanctis; V Bottari; A Frezzolini; M Ficcardi; G De Rossi; M C Petti; F Mandelli; L Fontana
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

2.  Recombinant interferon alpha 2 stimulation of target-binding by natural killer cells.

Authors:  E Heidemann; J Weber; H Schmidt; U Reichmann
Journal:  Klin Wochenschr       Date:  1986-10-15

3.  Application of a new method for detecting the phenotype of target binding cells.

Authors:  R A Lindemann; J A Jenkins; R A Figlin; S H Golub
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

4.  In vitro modulation of natural killer cell activity in non-Hodgkin's lymphoma patients after therapy.

Authors:  B A Mehta; M N Satam; S H Advani; J J Nadkarni
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

5.  NK cell activity and skin test antigen stimulation of NK like CMC in vitro are decreased to different degrees in pregnancy and sarcoidosis.

Authors:  D Tartof; J J Curran; S L Yang; C Livingston
Journal:  Clin Exp Immunol       Date:  1984-08       Impact factor: 4.330

6.  Acyclovir monotherapy versus acyclovir plus beta-interferon in focal viral encephalitis in children.

Authors:  U Wintergerst; B H Belohradsky
Journal:  Infection       Date:  1992 Jul-Aug       Impact factor: 3.553

7.  Analysis of natural killer activity and antibody-dependent cellular cytotoxicity in healthy volunteers and in patients with primary lung cancer and metastatic pulmonary tumors.

Authors:  N Saijo; E Shimizu; N Irimajiri; A Ozaki; K Kimura; T Takizawa; H Niitani
Journal:  J Cancer Res Clin Oncol       Date:  1982       Impact factor: 4.553

8.  Natural killing and growth inhibition of K562 cells by subpopulations of mononuclear cells as a function of target cell proliferation.

Authors:  G Hagner
Journal:  Immunology       Date:  1984-07       Impact factor: 7.397

9.  Studies of human natural killer cells. III. Neutropenia associated with unusual characteristics of antibody-dependent and natural killer cell-mediated cytotoxicity.

Authors:  H F Pross; J Pater; I Dwosh; A Giles; L A Gallinger; P Rubin; W E Corbett; P Galbraith; M G Baines
Journal:  J Clin Immunol       Date:  1982-04       Impact factor: 8.317

10.  Phenotypic and functional characterization of the circulating NK compartment in hairy cell leukaemia.

Authors:  R Foa; F Lauria; P Lusso; D Raspadori; M T Fierro; P L Tazzari; L Caudana; L Matera
Journal:  Clin Exp Immunol       Date:  1986-05       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.